Northwest Biotherapeutics signs $5.51M loan deal

The agreement provides for no repayments during the first eight months, followed by 14 monthly principal installments beginning June 26, 2027.

Available on EDGAR 10/30/2026 - 04:10 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:10 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Northwest Biotherapeutics, Inc. (NWBO) entered into a $5,505,000 commercial loan agreement with Streeterville Capital, LLC on October 26, 2026. The agreement has a 22-month maturity, bears interest at 8% per annum, and includes a 10% original issue discount. No repayments are due for the first eight months. Beginning June 26, 2027, principal will be amortized in 14 equal monthly installments at 110% of the pro rata amount, plus accrued interest.

The company may prepay at any time at its election, with a 10% charge. The funds will be used for ongoing business operations. The agreement includes customary default provisions, including potential acceleration.

Filing Explained

On October 26, 2026, NWBO entered a $5,505,000 loan agreement for ongoing operations, with scheduled repayment terms; its $595,000 cash at June 30, 2026 equaled 7.6 days of second-quarter operating cash use, a historical comparison rather than a forecast of the loan’s operating runway.

Sources and calculations

• Northwest Biotherapeutics Form 8-K (2026-10-26)
• Northwest Biotherapeutics 2026 second-quarter fundamentals (2026-06-30)

• Available liquidity against the last reported quarterly operating outflow, in days at that rate $595,000 / ($7,169,000 / 91) = 7.6 days

8-K Event Classification

2 items: 1.01, 2.03

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Key Figures

Loan amount: $5,505,000 Maturity: 22 months Interest rate: 8% per annum +5 more

8 metrics

Loan amount $5,505,000 Commercial loan agreement with Streeterville Capital, LLC

Maturity 22 months Loan agreement term

Interest rate 8% per annum Accrues on the loan agreement

Original issue discount 10% Included in the loan agreement

Initial repayment period 8 months No repayments are due during this period

Amortization start June 26, 2027 Beginning of scheduled principal installments

Principal installments 14 equal monthly installments At 110% of the pro rata amount, plus accrued interest

Prepayment charge 10% Applies if the company elects to prepay

Key Terms

original issue discount, amortized, pro rata amount, acceleration

4 terms

original issue discount financial

"includes an original issue discount of ten percent"

Original issue discount (OID) is the difference between a debt security’s face value and the lower price at which it is first sold, treated as additional interest that accrues over the life of the instrument. For investors it matters because OID raises the effective yield and changes taxable income and the holding’s cost basis over time — think of buying a $100 voucher for $90 and recognizing the $10 gain as earned interest as the voucher approaches maturity.

amortized financial

"will be amortized in 14 equal monthly installments"

Amortized means spreading a cost or a debt repayment into regular portions over a set period so each payment covers part of the principal and, if applicable, interest. For investors, knowing something is amortized shows how much of a company’s payments are scheduled over time, which affects cash flow, reported profits, and the remaining debt burden—similar to how a mortgage or installment plan breaks a large purchase into predictable monthly payments.

pro rata amount financial

"at 110% of the pro rata amount"

acceleration financial

"including for potential acceleration"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is NWBO's loan from Streeterville Capital?

Northwest Biotherapeutics entered into a commercial loan agreement with Streeterville Capital, LLC for $5,505,000, with a 22-month maturity. The funds will be used for the company's ongoing business operations.

When does NWBO start repaying the loan, and what are the installments?

No repayments are due for the first eight months. Beginning June 26, 2027, principal will be amortized in 14 equal monthly installments at 110% of the pro rata amount, plus accrued interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001072379 0001072379 2026-10-26 2026-10-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 26, 2026

Northwest Biotherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		0-35737		94-3306718
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

4800 Montgomery Lane, Suite 800

Bethesda, Maryland 20814

(Address of Principal Executive Offices)

(240) 497-9024

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.l4a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule l3e-4(c) under the Exchange Act (17 CFR 240. l3e-4(c))

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
Common Stock, par value, $0.001 per share		NWBO		OTCQB

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240. l2b-2 of this chapter).

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01. Entry into a Material Definitive Agreement.

Loan Entered Into

On October 26, 2026, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $5,505,000. The Loan Agreement has a maturity of 22 months. There are no repayments for the first 8 months.

Beginning on June 26, 2027, the Loan Agreement will be amortized in 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest on the Loan Agreement accrues at a rate of 8% per annum, and the Loan Agreement includes an original issue discount of ten percent. The Loan Agreement allows pre-payment at any time at the Company’s election. If the Company elects to pre-pay, the pre-payment would include a 10% charge. The Loan Agreement contains customary default provisions, including for potential acceleration.

The funds will be used for the Company’s ongoing business operations.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

2/3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NORTHWEST BIOTHERAPEUTICS, INC.
Date: October 30, 2026	By:	/s/ Linda Powers
	Name:	Linda Powers
	Title:	Chief Executive Officer and Chairman

3/3

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB